Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: results from a longitudinal cohort and mendelian randomization study
Baiyong Shen,Yanyun Li,Chang-Sheng Sheng,Lili Liu,Tianzhichao Hou,Nan Xia,Siming Sun,Ya Miao,Yi Pang,Kai Gu,Xiongxiong Lu,Chenlei Wen,Yi Cheng,Yulin Yang,Dan Wang,Yijie Zhu,Minna Cheng,Katie Harris,Zachary T. Bloomgarden,Jingyan Tian,John Chalmers,Yan Shi
DOI: https://doi.org/10.1016/j.lanwpc.2022.100596
IF: 8.559
2023-01-01
The Lancet Regional Health - Western Pacific
Abstract:Background The aim of the study is to estimate the incidence of pancreatic cancer among individuals with new -onset type 2 Diabetes (T2DM) and evaluate the relationship of pancreatic cancer risk with age at diabetes onset and diabetes duration. Methods This longitudinal cohort study included 428,362 new-onset T2DM patients in Shanghai and Mendelian randomization (MR) in the east-Asian population were used to investigate the association. Incidence rates of pancre-atic cancer in all patients and by subgroups were calculated and compared to the general population.Findings A total of 1056 incident pancreatic cancer cases were identified during eight consecutive years of follow-up. The overall pancreatic cancer annual incidence rate was 55.28/100,000 person years in T2DM patients, higher than that in the general population, with a standardized incidence ratio (SIR) of 1.54 (95% confidence interval [CI], 1.45- 1.64). The incidence of pancreatic cancer increased with age and a significantly higher incidence was observed in the older groups with T2DM. However, the relative pancreatic cancer risk was inversely related to age of T2DM onset, and a higher SIR of 5.73 (95%CI, 4.49-7.22) was observed in the 20-54 years old group. The risk of pancreatic cancer was elevated at any diabetes duration. Fasting blood glucose >= 10 cent 0 mmol/L was associated with increased risk of pancreatic cancer. MR analysis indicated a positive association between T2DM and pancreatic cancer risk.Interpretation Efforts toward early and close follow-up programs, especially in individuals with young-onset T2DM, and the improvement of glucose control might represent effective strategies for improving the detection and results of treatment of pancreatic cancer.